Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the role of BCMA CAR-T cells in the management of multiple myeloma

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the ...

Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies

Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies

Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and ...

Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her impression of the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her ...

Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ECHELON-2 data presented at ASH 2019

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ...

Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how JNJ-4528 differs from other CAR-T products

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how ...

Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the purpose of targeting peripheral t-cell lymphoma (PTCL)

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the ...

Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us about the outcomes of the CARTITUDE-1 investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma

Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us ...

Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should ...

Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the the primary and secondary endpoints of the ECHELON-2 study

Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the ...

Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL data presented at ASH 2019 investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL)

Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL ...